Therapeutic drug monitoring for triazoles

William W. Hope, Eliane M. Billaud, Jodie Lestner, David W. Denning

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Purpose of review: Invasive fungal infections are a leading cause of morbidity and mortality in immunocompromised patients, and mechanisms to optimize therapeutic outcomes are urgently required. Therapeutic drug monitoring represents an important component for the routine use of the triazoles. Recent findings: Triazoles have revolutionized the prevention and treatment of invasive fungal infections. Increasing data suggest that this class displays important concentration-effect and concentration-toxicity relationships. There has been an increased understanding of the pharmacokinetics and pharmacodynamics of triazoles, and this has facilitated the identification of concentrations (or drug exposures) that are both effective and nontoxic. This review discusses the application of therapeutic drug monitoring to fluconazole, itraconazole, voriconazole and posaconazole. Summary: Therapeutic drug monitoring represents an important mechanism to optimize the outcome of immunocompromised patients receiving triazoles. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.
    Original languageEnglish
    Pages (from-to)580-586
    Number of pages6
    JournalCurrent Opinion in Infectious Diseases
    Volume21
    Issue number6
    DOIs
    Publication statusPublished - Dec 2008

    Keywords

    • Fluconazole
    • Posaconazole
    • Therapeutic drug monitoring
    • Voriconazole

    Fingerprint

    Dive into the research topics of 'Therapeutic drug monitoring for triazoles'. Together they form a unique fingerprint.

    Cite this